Q32 Bio (Q32 Bio) Equity-to-Asset : 0.32 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Q32 Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $48.77 Mil. Q32 Bio's Total Assets for the quarter that ended in Mar. 2024 was $152.33 Mil.

The historical rank and industry rank for Q32 Bio's Equity-to-Asset or its related term are showing as below:

QTTB' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.52 Med: -0.31 Max: 0.63
Current: 0.32

During the past 3 years, the highest Equity to Asset Ratio of Q32 Bio was 0.63. The lowest was -1.52. And the median was -0.31.

QTTB's Equity-to-Asset is ranked worse than
75.22% of 1562 companies
in the Biotechnology industry
Industry Median: 0.67 vs QTTB: 0.32

Q32 Bio Equity-to-Asset Historical Data

The historical data trend for Q32 Bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Equity-to-Asset Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Equity-to-Asset

0.63

-0.31

-1.52

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial			-0.31	-	-0.84	-1.52	0.32

Competitive Comparison of Q32 Bio's Equity-to-Asset

For the Biotechnology subindustry, Q32 Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Equity-to-Asset falls into.

Q32 Bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Q32 Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-71.476	/	47.057
	=	-1.52

Q32 Bio's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	48.769	/	152.334
	=

Q32 Bio (NAS:QTTB) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Q32 Bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024